Actively Recruiting
Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans
Led by Nicolai Jacob Wewer Albrechtsen · Updated on 2024-10-17
6
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
Sponsors
N
Nicolai Jacob Wewer Albrechtsen
Lead Sponsor
U
University Hospital Bispebjerg and Frederiksberg
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied. The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism. We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate. Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.
CONDITIONS
Official Title
Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the participant information and sign the consent form
- Between 25 and 70 years of age
- Body mass index (BMI) of 25 kg/m^2 or less
You will not qualify if you...
- Enrolled in other research projects that could interfere with this study
- Diagnosis of diabetes
- Pregnant or breastfeeding
- Use of medications that may risk safety or compliance as judged by the investigator
- Diagnosis of psychiatric, dementia, or neurological disorders that affect compliance or safety
- Severe claustrophobia
- Cardiac problems including NYHA class III or IV, recent angina pectoris within 6 months, or heart attack within 2 years
- Blood pressure outside 90-150 mmHg systolic or 50-100 mmHg diastolic at screening
- Active or recent cancer
- Current or past severe alcohol or drug abuse as judged by the investigator
- Any chronic or severe diseases that may risk safety or compliance as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Physiology and Nuclear Medicine, University of Copenhagen - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Copenhagen, Denmark, 2400
Actively Recruiting
Research Team
N
Nina L Hansen, MD
CONTACT
S
Sasha Alexandra S Kjeldsen, MSc PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here